DelveInsight’s, “Polycystic Kidney Diseases Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycystic Kidney Diseases pipeline landscape. It covers the Polycystic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Polycystic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Polycystic Kidney Disease Pipeline. Dive into DelveInsight’s comprehensive report today! @ Polycystic Kidney Disease Pipeline Outlook
Key Takeaways from the Polycystic Kidney Disease Pipeline Report
- In June 2025, Biogen announced a Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare CKD.
- DelveInsight’s Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycystic Kidney Disease treatment.
- The leading Polycystic Kidney Disease Companies such as Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc. and others.
- Promising Polycystic Kidney Disease Pipeline Therapies such as Rapamune, Lisinopril, Telmisartan, Empagliflozin 10 MG, Everolimus, Bosutinib, Tolvaptan MR and others.
Stay ahead with the most recent pipeline outlook for Polycystic Kidney Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Polycystic Kidney Disease Treatment Drugs
Polycystic Kidney Disease Emerging Drugs Profile
- Tamibarotene: Rege Nephro Co., Ltd.
Tamibarotene, developed by Rege Nephro Co., Ltd., is a retinoic acid receptor (RAR) agonist currently undergoing clinical trials for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This drug, also known by its investigational code RN-014, is designed to inhibit cyst formation and improve renal function in patients suffering from this hereditary condition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Autosomal dominant polycystic kidney disease (ADPKD).
- RGLS8429: Regulus Therapeutics Inc.
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown data in preclinical models, where improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus’ first-generation compound, RGLS4326. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Polycystic Kidney Disease.
- AL1311: AceLink Therapeutics, Inc.
AL1311 is a highly potent NRF2 activator that is being developed for Autosomal Dominant Polycystic Kidney disease (ADPKD). AL1311 is different from other electrophilic and reactive NRF2 activators because it works by disrupting the protein-protein interaction between NRF2 and its regulatory protein Keap1. Non-reactive NRF2 activators have the potential to have better specificity for NRF2 activation and therefore a better safety profile. Currently, the drug is in Preclinical stage of development for the treatment of Polycystic Kidney Disease.
The Polycystic Kidney Disease Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
- Polycystic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market
Explore groundbreaking therapies and clinical trials in the Polycystic Kidney Disease Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Drugs for Polycystic Kidney Disease
Polycystic Kidney Disease Companies
Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc. and others.
Polycystic Kidney Diseases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Polycystic Kidney Disease Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Polycystic Kidney Disease Treatment. Learn about new drugs of Polycystic Kidney Disease, pipeline developments, and key companies with DelveInsight’s expert analysis @ Polycystic Kidney Disease Market Drivers and Barriers
Scope of the Polycystic Kidney Disease Pipeline Report
- Coverage- Global
- Polycystic Kidney Disease Companies- Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc. and others.
- Polycystic Kidney Disease Pipeline Therapies- Rapamune, Lisinopril, Telmisartan, Empagliflozin 10 MG, Everolimus, Bosutinib, Tolvaptan MR and others.
- Polycystic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Polycystic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Polycystic Kidney Disease Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Polycystic Kidney Disease Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Polycystic Kidney Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Polycystic Kidney Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Tamibarotene: Rege Nephro Co., Ltd.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RGLS8429: Regulus Therapeutics Inc.
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AL1311: AceLink Therapeutics, Inc.
- Inactive Products
- Polycystic Kidney Disease Key Companies
- Polycystic Kidney Disease Key Products
- Polycystic Kidney Disease- Unmet Needs
- Polycystic Kidney Disease- Market Drivers and Barriers
- Polycystic Kidney Disease- Future Perspectives and Conclusion
- Polycystic Kidney Disease Analyst Views
- Polycystic Kidney Disease Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight